Skip to content
CharitiesAidWelfare, Medical Health Aged Care

Leukaemia Foundation welcomes Professor James Ward to its Board

Leukaemia Foundation 2 mins read

The Leukaemia Foundation is pleased to announce the appointment of Professor James Ward to its Board, effective immediately.

Professor Ward brings a wealth of experience, a strong commitment to equity, and deep expertise in Indigenous health – qualities that will be invaluable as we intensify our efforts to support all Australians impacted by blood cancer.

Professor Ward is a proud Pitjantjatjara and Narungga man and currently serves as Director of the University of Queensland Poche Centre for Indigenous Health (since 2020).

For nearly three decades, he has driven community-led public health and infectious disease research, forging policy and research partnerships across more than 100 Indigenous communities, and influencing clinical practice and national guidelines.

Previously, Professor Ward was Head of Infection and Immunity – Aboriginal Health at the South Australian Health and Medical Research Institute (SAHMRI) from 2014 to 2019.

He is a Fellow of the Australian Academy of Health and Medical Sciences and an Australian Research Council Laureate Fellow, holding a PhD and deep expertise in systems change, equity, and collaboration with the Aboriginal community-controlled health sector.

“We are honoured to welcome Professor Ward to our Board,” said Lucio Di Giallonardo, Leukaemia Foundation Board Chair.

“His leadership and experience will strengthen our capacity to address the unacceptable disparities in blood cancer diagnosis, treatment and survivorship faced by First Nations Australians.

“And his voice will help ensure our policies, support services and advocacy truly reflect the needs of all Australians facing a blood cancer diagnosis.”

With Professor Ward’s guidance and support, the Leukaemia Foundation is more committed than ever to: 

  • Ensuring equitable access to diagnosis, treatment and support services for First Nations communities and other underserved populations;
  • Shaping research, support and advocacy in a way that recognises and responds to systemic inequities in health outcomes;
  • Strengthening partnerships across the Indigenous health sector, with researchers and clinicians to improve outcomes for First Nations Australians and all blood cancer patients.

“We believe that blood cancer does not, and should not, discriminate and neither should care, support or hope,” said Mr Di Giallonardo.

“With Professor Ward joining our Board, we take a bold step forward in ensuring that the inequalities that have persisted for too long are addressed head-on.

“His leadership will help us continue the fight for every Australian affected by blood cancer — no matter who they are or where they live.”

For more information on Professor Ward and the Leukaemia Foundation Board visit leukeamia.org.au.

-END-


About us:

About the Leukaemia Foundation: The Leukaemia Foundation stands with Australia to help cure and conquer blood cancer – with care. Together we are attacking every blood cancer, from every direction, in every way we can. We stand beside every Australian to be their voice and their someone-to-turn to, fighting to get them access to the best care. We also accelerate research that is delivering rapid advancements in blood cancer diagnosis and treatments. Plus, we provide services and support that empower people living with any blood cancer to live well after diagnosis. You can learn more about the Leukaemia Foundation and blood cancer at leukaemia.org.au


Contact details:

Please contact the Leukaemia Foundation media team at [email protected] or call 0473 154 079.

More from this category

  • Business Company News, Medical Health Aged Care
  • 13/01/2026
  • 10:50
Nova Eye Medical (ASX:EYE)

Nova Eye Medical Reports Record Sales Result for December 2025 Quarter

HIGHLIGHTS Record December quarter with global sales of US$6.1 million, up 38% on pcp and 25% on the September 2025 quarter Global six-month sales…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 13/01/2026
  • 10:09
Jane Morgan Management

NeuroScientific Biopharmaceuticals (ASX:NSB) Reports Clinical Response for StemSmart(TM) Treatment in Fistulising Crohn’s Disease Under Special Access Program

13 January 2026 – Perth, Australia | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has today announced a “Clinical Response” from patients treated with its patented StemSmart™ Mesenchymal Stem Cell (MSC) therapy under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS) for fistulising Crohn’s disease. Three of four patients treated in Cohort 1 of the Special Access Program demonstrated a successful “Clinical Response” following treatment with StemSmart™, with the fourth patient showing a partial response with further clinical assessment needed. A Clinical Response is defined as either closure of at least 50 per cent of fistula openings or a reduction in fistula…

  • Contains:
  • Medical Health Aged Care
  • 13/01/2026
  • 10:08
Dementia Australia

Community grants to boost dementia-friendly initiatives across Australia

Dementia Australia has today opened applications foranewround ofCommunity Engagementgrantsforup to12dementia-friendly community initiatives. Dementia Australia CEO Professor Tanya Buchanan saidcommunity groupscouldapply for up to $10,000for…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.